Sanara MedTech Inc (SMTI, Financial) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $20.70 million, and the earnings are expected to come in at -$0.62 per share. The full year 2024's revenue is expected to be $80.90 million and the earnings are expected to be -$2.03 per share. More detailed estimate data can be found on the Forecast page.
Sanara MedTech Inc (SMTI, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Sanara MedTech Inc (SMTI) for the full year 2024 have increased from $77.30 million to $80.90 million. For 2025, these estimates have risen from $88.60 million to $96.20 million. However, earnings estimates have shown a decline; for the full year 2024, estimates decreased from -$0.79 per share to -$2.03 per share, and for 2025, they declined from -$0.11 per share to -$1.17 per share.
Sanara MedTech Inc (SMTI, Financial) Reported History
In the previous quarter of 2024-06-30, Sanara MedTech Inc's (SMTI) actual revenue was $20.16 million, which beat analysts' revenue expectations of $19.10 million by 5.54%. Sanara MedTech Inc's (SMTI) actual earnings were -$0.41 per share, which missed analysts' earnings expectations of -$0.21 per share by 95.24%. After releasing the results, Sanara MedTech Inc (SMTI) was up by 15.13% in one day.
Sanara MedTech Inc (SMTI, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 1 analyst, the average target price for Sanara MedTech Inc (SMTI) is $44 with a high estimate of $44 and a low estimate of $44. The average target implies an upside of 24.86% from the current price of $35.24.
Based on GuruFocus estimates, the estimated GF Value for Sanara MedTech Inc (SMTI, Financial) in one year is $78.43, suggesting an upside of 122.56% from the current price of $35.24.
Based on the consensus recommendation from 1 brokerage firm, Sanara MedTech Inc's (SMTI, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
